NovaBiotics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 4

NovaBiotics General Information

Description

Operator of a clinical-stage biotechnology company intended to develop therapies to treat medically unmet diseases. The company's therapies focus on the development of antibacterial and antifungal candidates for the treatment of invasive fungal diseases caused by mold and emerging drug-resistant yeasts, enabling researchers to study antifungal peptides in development to prevent and treat life-limiting inflammatory, infectious, and respiratory diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • ONE BioHub, Foresterhill Road
  • Aberdeen AB25 2XE
  • Scotland, United Kingdom
+44 01224
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • ONE BioHub, Foresterhill Road
  • Aberdeen AB25 2XE
  • Scotland, United Kingdom
+44 01224

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NovaBiotics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC Completed Generating Revenue
10. Secondary Transaction - Private 01-Feb-2021 Completed Generating Revenue
9. Grant 16-Oct-2020 Completed Generating Revenue
8. Grant 19-Mar-2019 Completed Generating Revenue
7. Grant 01-Jan-2019 Completed Generating Revenue
6. Later Stage VC 03-Mar-2017 Completed Generating Revenue
5. Later Stage VC 19-Jan-2015 Completed Startup
4. Later Stage VC 14-Mar-2012 Completed Startup
3. Later Stage VC 25-Nov-2011 $9.5M $9.5M Completed Startup
2. Grant 10-Sep-2009 $361K Completed Startup
To view NovaBiotics’s complete valuation and funding history, request access »

NovaBiotics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 7
Ordinary 6
Ordinary 5
Ordinary A
Ordinary 4
Ordinary 3
Ordinary 2 2,043,642 $0.158951 $1.2 $1.2 1x $1.2 19.4%
Ordinary 1 1,400,368 $0.158951 $1.19 $1.19 1x $1.19 13.3%
To view NovaBiotics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NovaBiotics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company intended to develop therapies to treat medically unmet diseases. The
Biotechnology
Aberdeen, United Kingdom
15 As of 2026

Malvern, PA
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NovaBiotics Competitors (43)

One of NovaBiotics’s 43 competitors is Venatorx Pharmaceuticals, a Venture Capital-Backed company based in Malvern, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Venatorx Pharmaceuticals Venture Capital-Backed Malvern, PA
Eligo Bioscience Venture Capital-Backed Paris, France
Seres Therapeutics Formerly VC-backed Cambridge, MA
Rein Therapeutics Formerly VC-backed Austin, TX
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 43 competitors. Get the full list »

NovaBiotics Patents

NovaBiotics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202418321-D0 Next generation delivery of antimicrobial peptides Inactive 13-Dec-2024
AU-2025206098-A1 Compositions to improve the condition and/or appearance of keratinised tissue Pending 05-Jan-2024
EP-4836752-A1 Compositions to improve the condition and/or appearance of keratinised tissue Pending 05-Jan-2024
WO-2025146549-A1 Compositions to improve the condition and/or appearance of keratinised tissue Inactive 05-Jan-2024
GB-202400182-D0 Improved compositions to improve the appearance and/or condition of skin, scalp, nail and/or hair Inactive 05-Jan-2024 A61K8/88
To view NovaBiotics’s complete patent history, request access »

NovaBiotics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NovaBiotics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
U.K. Department of Health & Social Care Government Minority
Innovate UK Government
University College London University
Acacia Research Corporation Minority
To view NovaBiotics’s complete investors history, request access »

NovaBiotics FAQs

  • When was NovaBiotics founded?

    NovaBiotics was founded in 2004.

  • Where is NovaBiotics headquartered?

    NovaBiotics is headquartered in Aberdeen, United Kingdom.

  • What is the size of NovaBiotics?

    NovaBiotics has 15 total employees.

  • What industry is NovaBiotics in?

    NovaBiotics’s primary industry is Biotechnology.

  • Is NovaBiotics a private or public company?

    NovaBiotics is a Private company.

  • What is NovaBiotics’s current revenue?

    The current revenue for NovaBiotics is .

  • How much funding has NovaBiotics raised over time?

    NovaBiotics has raised $35.9M.

  • Who are NovaBiotics’s investors?

    U.K. Department of Health & Social Care, Innovate UK, University College London, and Acacia Research have invested in NovaBiotics.

  • Who are NovaBiotics’s competitors?

    Venatorx Pharmaceuticals, Eligo Bioscience, Seres Therapeutics, Rein Therapeutics, and Vedanta Biosciences are some of the 43 competitors of NovaBiotics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process